cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.19241973.v2
title: Evaluating the effectiveness of integrating digital technology into orthodontic cephalometric measurement teaching

description: The original results of the pedagogical experiments integrating the digital technology into the cephalometric measurement teaching.
DOI: 10.6084/m9.figshare.19241973.v1
title: Evaluating the effectiveness of integrating digital technology into orthodontic cephalometric measurement teaching

description: The original results of the pedagogical experiments integrating the digital technology into the cephalometric measurement teaching.
DOI: 10.25345/c5tb0xw9k
title: MassIVE MSV000088935 - Going BEEyond: Philippine Forest Nectars Dataset
title: Dataset on Nectar Sources to aid in quality and environmental studies associated to Philippine Forest Honey and Propolis. Grant 2021-06 funded by Forest Foundation Philippines
DOI: 10.5281/zenodo.6317472
title: Herbal plants for RIFA management

description: This dataset is used to evaluate the feasibility of planting herbal species for RIFA control.
description: This work was supported by the Ministry of Science and Technology, R.O.C. [MOST 110-2327-B-041-001 and MOST 108-2638-H-002-001-MY2].
DOI: 10.5281/zenodo.6317471
title: Herbal plants for RIFA management

description: This dataset is used to evaluate the feasibility of planting herbal species for RIFA control.
description: This work was supported by the Ministry of Science and Technology, R.O.C. [MOST 110-2327-B-041-001 and MOST 108-2638-H-002-001-MY2].
DOI: 10.6084/m9.figshare.19254544
title: Additional file 1 of A 6.3 Mb maternally derived microduplication of 20p13p12.2 in a fetus with Brachydactyly type D and related literature review

description: Additional file 1. Table S1: The bioinformatic quality index of Trio ES of the fetus and mother and Table S2: The 6.3 Mb microduplication on chromosome 20 was detected by Trio ES data of the fetus and mother.
DOI: 10.6084/m9.figshare.19254544.v1
title: Additional file 1 of A 6.3 Mb maternally derived microduplication of 20p13p12.2 in a fetus with Brachydactyly type D and related literature review

description: Additional file 1. Table S1: The bioinformatic quality index of Trio ES of the fetus and mother and Table S2: The 6.3 Mb microduplication on chromosome 20 was detected by Trio ES data of the fetus and mother.
DOI: 10.6084/m9.figshare.19128577
title: Additional file 1 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 1: Table S1. Raw of 1288 differentialy methylated genes in Left and Right xenograft tumors.
DOI: 10.6084/m9.figshare.19128577.v2
title: Additional file 1 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 1: Table S1. Raw of 1288 differentialy methylated genes in Left and Right xenograft tumors.
DOI: 10.6084/m9.figshare.19128580
title: Additional file 2 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 2: Table S2: Raw data of 2997 differentialy methylated genes from Left and Right in-silico breast tumors.
DOI: 10.6084/m9.figshare.19128577.v1
title: Additional file 1 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 1: Table S1. Raw of 1288 differentialy methylated genes in Left and Right xenograft tumors.
DOI: 10.6084/m9.figshare.19128583
title: Additional file 3 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 3: Table S3. Raw data of DiBAC fluorescence measured by flow cytometry in Left and Right extract-treated cells.
DOI: 10.6084/m9.figshare.19128580.v2
title: Additional file 2 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 2: Table S2: Raw data of 2997 differentialy methylated genes from Left and Right in-silico breast tumors.
DOI: 10.6084/m9.figshare.19128583.v2
title: Additional file 3 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 3: Table S3. Raw data of DiBAC fluorescence measured by flow cytometry in Left and Right extract-treated cells.
DOI: 10.6084/m9.figshare.19128583.v1
title: Additional file 3 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 3: Table S3. Raw data of DiBAC fluorescence measured by flow cytometry in Left and Right extract-treated cells.
DOI: 10.6084/m9.figshare.19128580.v1
title: Additional file 2 of When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer

description: Additional file 2: Table S2: Raw data of 2997 differentialy methylated genes from Left and Right in-silico breast tumors.
DOI: 10.6084/m9.figshare.19254661
title: Additional file 1 of Anaerobic derivates of mitochondria and peroxisomes in the free-living amoeba Pelomyxa schiedti revealed by single-cell genomics

description: Additional file 1: Table S1. Statistics of Pelomyxa schiedti assemblies were compared with those of Mastigamoeba balamuthi. Table S2. Proteins targeted to MRO of Pelomyxa schiedti. Localization of proteins was predicted by several tools, as listed in columns E - J. Mitochondrial predictions are highlighted by white text on blue background. Column K shows final inferred prediction of localization. Abbreviations: cyt, cytosolic; ER, endoplasmic reticulum; extracell, extracellular; mit, mitochondrial; nuc, nuclear; Other, other localization; perox, peroxisomal; PM, plasma membrane; sec, secretory system; SP, signal peptide; -, protein not localized in MRO; +, protein localized in MRO; +?, protein localized in MRO with low confidence. Table S3. Proteins required for peroxisome biogenesis and targeted to peroxisome. Proteins identified in Mastigamoeba balamuthi are highlighted by white text on blue background. Proteins were considered peroxisome-targeted, if they contained PTS1 (SRI or [SAP][KR][LM]) or PTS2 motif (R[LIV](x5)HL), and/or were predicted by PTS1 predictor [83]. Table S4. Primers used in this study.
DOI: 10.6084/m9.figshare.19254661.v1
title: Additional file 1 of Anaerobic derivates of mitochondria and peroxisomes in the free-living amoeba Pelomyxa schiedti revealed by single-cell genomics

description: Additional file 1: Table S1. Statistics of Pelomyxa schiedti assemblies were compared with those of Mastigamoeba balamuthi. Table S2. Proteins targeted to MRO of Pelomyxa schiedti. Localization of proteins was predicted by several tools, as listed in columns E - J. Mitochondrial predictions are highlighted by white text on blue background. Column K shows final inferred prediction of localization. Abbreviations: cyt, cytosolic; ER, endoplasmic reticulum; extracell, extracellular; mit, mitochondrial; nuc, nuclear; Other, other localization; perox, peroxisomal; PM, plasma membrane; sec, secretory system; SP, signal peptide; -, protein not localized in MRO; +, protein localized in MRO; +?, protein localized in MRO with low confidence. Table S3. Proteins required for peroxisome biogenesis and targeted to peroxisome. Proteins identified in Mastigamoeba balamuthi are highlighted by white text on blue background. Proteins were considered peroxisome-targeted, if they contained PTS1 (SRI or [SAP][KR][LM]) or PTS2 motif (R[LIV](x5)HL), and/or were predicted by PTS1 predictor [83]. Table S4. Primers used in this study.
DOI: 10.6084/m9.figshare.19254670.v1
title: Additional file 2 of Dynamic profiles of DNA methylation and the interaction with histone acetylation during fiber cell initiation of Gossypium hirsutum

description: Additional file 2. Table S1. Gene names and ID from the updated genome assembly with de novo technology.
DOI: 10.6084/m9.figshare.19254673.v1
title: Additional file 3 of Dynamic profiles of DNA methylation and the interaction with histone acetylation during fiber cell initiation of Gossypium hirsutum

description: Additional file 3. Table S2. Primers used in this study.
DOI: 10.6084/m9.figshare.19254670
title: Additional file 2 of Dynamic profiles of DNA methylation and the interaction with histone acetylation during fiber cell initiation of Gossypium hirsutum

description: Additional file 2. Table S1. Gene names and ID from the updated genome assembly with de novo technology.
DOI: 10.6084/m9.figshare.19254673
title: Additional file 3 of Dynamic profiles of DNA methylation and the interaction with histone acetylation during fiber cell initiation of Gossypium hirsutum

description: Additional file 3. Table S2. Primers used in this study.
DOI: 10.6084/m9.figshare.19254732
title: Additional file 1 of Point-of-care urine Gram stain led to narrower-spectrum antimicrobial selection for febrile urinary tract infection in adolescents and adults

description: Additional file 1. Original dataset.
DOI: 10.6084/m9.figshare.19254732.v1
title: Additional file 1 of Point-of-care urine Gram stain led to narrower-spectrum antimicrobial selection for febrile urinary tract infection in adolescents and adults

description: Additional file 1. Original dataset.
DOI: 10.6084/m9.figshare.19254744
title: Additional file 10 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 10: Supplementary Table 9. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254744.v1
title: Additional file 10 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 10: Supplementary Table 9. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254747.v1
title: Additional file 11 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 11: Supplementary Table 10. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254750
title: Additional file 12 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 12: Supplementary Table 11. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among prostate cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254750.v1
title: Additional file 12 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 12: Supplementary Table 11. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among prostate cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254753
title: Additional file 13 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 13: Supplementary Table 12. Univariable and multivariable quantile regression for OF4 for colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254747
title: Additional file 11 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 11: Supplementary Table 10. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254756
title: Additional file 14 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 14: Supplementary Table 13. Univariable and multivariable quantile regression for OF4 for rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254756.v1
title: Additional file 14 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 14: Supplementary Table 13. Univariable and multivariable quantile regression for OF4 for rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254753.v1
title: Additional file 13 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 13: Supplementary Table 12. Univariable and multivariable quantile regression for OF4 for colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254759
title: Additional file 15 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 15: Supplementary Table 14. Univariable and multivariable quantile regression for OF4 for lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254759.v1
title: Additional file 15 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 15: Supplementary Table 14. Univariable and multivariable quantile regression for OF4 for lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254765
title: Additional file 17 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 17: Supplementary Table 16. Univariable and multivariable quantile regression for OF4 for prostate cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254762
title: Additional file 16 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 16: Supplementary Table 15. Univariable and multivariable quantile regression for OF4 for breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254762.v1
title: Additional file 16 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 16: Supplementary Table 15. Univariable and multivariable quantile regression for OF4 for breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254765.v1
title: Additional file 17 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 17: Supplementary Table 16. Univariable and multivariable quantile regression for OF4 for prostate cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254771.v1
title: Additional file 2 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 2: Supplementary Table 1. Definition of “Treatment hospital in health trust” for each health trust by surgery and radiotherapy and cancer type.
DOI: 10.6084/m9.figshare.19254774
title: Additional file 3 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 3: Supplementary Table 2. Patient characteristics by part of the cancer patient pathway for colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254771
title: Additional file 2 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 2: Supplementary Table 1. Definition of “Treatment hospital in health trust” for each health trust by surgery and radiotherapy and cancer type.
DOI: 10.6084/m9.figshare.19254774.v1
title: Additional file 3 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 3: Supplementary Table 2. Patient characteristics by part of the cancer patient pathway for colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254777.v1
title: Additional file 4 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 4: Supplementary Table 3. Patient characteristics by part of the cancer patient pathway for rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254777
title: Additional file 4 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 4: Supplementary Table 3. Patient characteristics by part of the cancer patient pathway for rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254780
title: Additional file 5 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 5: Supplementary Table 4. Patient characteristics by part of the cancer patient pathway for lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254783
title: Additional file 6 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 6: Supplementary Table 5. Patient characteristics by part of the cancer patient pathway for breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254786
title: Additional file 7 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 7: Supplementary Table 6. Patient characteristics by part of the cancer patient pathway for prostate cancer patients diagnosed in 2015-2016 in Norway.
DOI: 10.6084/m9.figshare.19254780.v1
title: Additional file 5 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 5: Supplementary Table 4. Patient characteristics by part of the cancer patient pathway for lung cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254783.v1
title: Additional file 6 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 6: Supplementary Table 5. Patient characteristics by part of the cancer patient pathway for breast cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254786.v1
title: Additional file 7 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 7: Supplementary Table 6. Patient characteristics by part of the cancer patient pathway for prostate cancer patients diagnosed in 2015-2016 in Norway.
DOI: 10.6084/m9.figshare.19254789
title: Additional file 8 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 8: Supplementary Table 7. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254795
title: Additional file 9 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 9: Supplementary Table 8. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254795.v1
title: Additional file 9 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 9: Supplementary Table 8. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among rectal cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254789.v1
title: Additional file 8 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016

description: Additional file 8: Supplementary Table 7. The proportion of OF1, OF2, OF3 and OF4 within the recommended time frames among colon cancer patients diagnosed in 2015–2016 in Norway.
DOI: 10.6084/m9.figshare.19254811
title: Additional file 2 of The core root microbiome of Spartina alterniflora is predominated by sulfur-oxidizing and sulfate-reducing bacteria in Georgia salt marshes, USA

description: Additional file 1. Table S1: List of genera containing species with known sulfate reducing, sulfur oxidizing, iron oxidizing, and nitrifying activity.
DOI: 10.6084/m9.figshare.19254811.v1
title: Additional file 2 of The core root microbiome of Spartina alterniflora is predominated by sulfur-oxidizing and sulfate-reducing bacteria in Georgia salt marshes, USA

description: Additional file 1. Table S1: List of genera containing species with known sulfate reducing, sulfur oxidizing, iron oxidizing, and nitrifying activity.
DOI: 10.6084/m9.figshare.19254847.v1
title: Additional file 1 of DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors

description: Additional file 1. Supplementary tables S1-S19.
DOI: 10.6084/m9.figshare.19254847
title: Additional file 1 of DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors

description: Additional file 1. Supplementary tables S1-S19.